Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus KYZATREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus KYZATREX.
ANDROID 5 vs KYZATREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Kyzatrex is a synthetic analog of human growth hormone (hGH). It binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, which stimulates insulin-like growth factor 1 (IGF-1) production in the liver and other tissues, promoting growth and anabolic effects.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
400 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life is 18 hours (range 14-22 h) in adults with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life prolongs to 28 hours; in severe impairment (CrCl <30 mL/min), half-life exceeds 40 hours, necessitating dose adjustment.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily renal excretion (85% unchanged, with active tubular secretion). Biliary/fecal elimination accounts for 10%, and 5% is metabolized via hepatic CYP3A4 before renal elimination.
Category C
Category C
Androgen
Androgen